Aldeyra's Phase III Data Show Positive Results for Eye Treatment

Aldeyra Therapeutics has reported that its Phase III trial of Reproxalap, a drug for treating allergic conjunctivitis and dry-eye disease, has produced positive results. The liquid eye drop formulation of the small-molecule modulator of reactive aldehyde species demonstrated statistically significant reductions in eye itchiness across the 11 primary endpoint comparisons for patients treated with..